Nektar Therapeutics (NKTR) Tops Q3 EPS by 17c

Nektar Therapeutics (NASDAQ: NKTR) reported Q3 EPS of ($0.56), $0.17 better than the analyst estimate of ($0.73). Revenue for the quarter came in at $29.2 million versus the consensus estimate of $26.4 million.

"We continue to make steady progress with our diverse portfolio of immuno-oncology and immunology programs," said Howard W. Robin, President and CEO of Nektar. "With our partner Bristol-Myers Squibb, we are conducting registrational trials evaluating the combination of bempegaldesleukin with nivolumab in melanoma, urothelial cancer and renal cell carcinoma. We are also working collaboratively with BMS to finalize the next set of registrational studies. This weekend at the SITC Annual Meeting, we are excited to present an 18-month follow-up for patients with metastatic melanoma enrolled in our PIVOT-02 study. This follows the recent announcement of our Breakthrough Therapy Designation for the doublet which was granted by FDA in August for patients with previously untreated metastatic melanoma. For NKTR-358, we now have three separate Phase 1b clinical trials ongoing in lupus, psoriasis and atopic dermatitis with our partner Eli Lilly, with plans to add an additional autoimmune indication to the development program in 2020. And importantly, we initiated our first clinical trial for NKTR-255, our novel IL-15 agonist, in patients with non-Hodgkin lymphoma and multiple myeloma."

For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Barclays Starts DKSH Holding AG (DKSH:SW) at Overweight
• Jefferies Reinstates Talen Energy (TLN) at Hold